Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs...

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Epidemiology

Background:

• Potassium chloride is widely prescribed for hypokalemia.
• Different formulations of potassium chloride exist, potentially varying in gastrointestinal safety.
• Upper gastrointestinal (UGI) tract bleeding is a known risk associated with oral medications.

Purpose of the Study:

• To compare the relative risk of upper gastrointestinal (UGI) tract bleeding between microencapsulated and wax-matrix potassium chloride formulations.
• To identify potential differences in gastrointestinal safety profiles of potassium chloride preparations.

Main Methods:

• Retrospective cohort study utilizing Medicaid billing data (1980-1984) from four US states.
• Analysis included patients exclusively dispensed either microencapsulated (28,790) or wax-matrix (76,118) potassium chloride.
• Logistic regression was used to adjust for confounding variables, examining UGI bleeding risk within 30 days of prescription.

Main Results:

• An odds ratio of 0.67 (95% CI, 0.52 to 0.85) was observed, indicating a reduced risk of UGI tract bleeding with the microencapsulated formulation.
• The study adjusted for multiple potential confounding factors in the analysis.

Conclusions:

• Microencapsulated potassium chloride appears to be associated with a significantly lower risk of upper gastrointestinal tract bleeding compared to the wax-matrix formulation.
• These findings suggest formulation type is an important consideration for minimizing gastrointestinal adverse events in potassium chloride therapy.